What Is AOD-9604? Modified GH Fragment Research Overview

Introduction to AOD-9604

AOD-9604 is a synthetic peptide corresponding to a modified fragment of human growth hormone (hGH), specifically amino acids 176-191 of the hGH sequence. Identified under CAS number 221231-10-3, the compound has been the subject of published in-vitro research investigating lipolytic signaling pathways and the functional dissection of growth hormone's molecular activities. The peptide's significance in the research literature stems from its documented ability to activate specific signaling cascades in cell-based assay systems while not engaging others -- a property that makes it a valuable tool for studying pathway-specific effects in controlled laboratory environments.

The compound was originally developed by researchers at Monash University in Melbourne, Australia, and first described in peer-reviewed publications in the late 1990s. The "AOD" designation stands for "Anti-Obesity Drug," reflecting the original research context, though the compound is now used broadly as a research tool in multiple areas of in-vitro investigation. Origin Research Labs provides AOD-9604 at >99.760% purity, independently verified by Janoshik Analytical.

From Full-Length hGH to Fragment 176-191

Human growth hormone is a 191 amino acid protein with multiple documented activities when studied in cell-based assay systems. Early structure-function research demonstrated that different regions of the hGH molecule are responsible for distinct biological activities, as measured by various in-vitro readouts. This modular activity profile led researchers to investigate whether isolated fragments could reproduce specific subsets of hGH signaling activity in controlled laboratory systems.

The C-terminal region of hGH, encompassing amino acids 176-191, was identified through systematic fragment screening as a region of interest for lipolysis-related research. Published studies using truncation and deletion mapping approaches demonstrated that this 16 amino acid region, when synthesized as an isolated peptide, retained measurable activity in specific in-vitro lipid metabolism assays while not activating the signaling pathways associated with other regions of the hGH molecule.

The modification that distinguishes AOD-9604 from the native hGH 176-191 fragment is the addition of a tyrosine residue at the N-terminus. This modification was introduced by the original research group to improve the peptide's stability and detection characteristics in laboratory assay systems. The resulting 16 amino acid peptide (Tyr + hGH 177-191) has since become the standard research form studied in the published literature.

Lipolytic Activity Research In Vitro

The primary area of published in-vitro research on AOD-9604 involves its effects on lipid metabolism pathways in cultured cell systems. Multiple independent research groups have published data using adipocyte cell lines, primary adipocyte cultures, and differentiated pre-adipocyte preparations to examine the peptide's effects on lipolysis-related endpoints.

Published In-Vitro Lipolysis Studies

Researchers have employed several standardized assay platforms to characterize AOD-9604's effects on lipolytic signaling in vitro:

• Glycerol release assays: Measurement of glycerol liberated into culture media as a quantitative marker of triglyceride hydrolysis in adipocyte cultures exposed to AOD-9604
• Free fatty acid release assays: Quantification of non-esterified fatty acids released from cultured adipocytes as a parallel lipolysis endpoint
• Lipase activity assays: Cell-free and cell-based enzyme activity measurements examining the effects of AOD-9604 on hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) activity
• Lipid droplet morphometry: Fluorescence microscopy-based quantification of intracellular lipid droplet size and number in cultured adipocytes following peptide exposure

Published data from these assay systems, reported in journals including the Journal of Endocrinology and Obesity Research, document measurable effects of AOD-9604 on lipolytic endpoints in cultured cell systems. It is critical to note that these observations were made exclusively in in-vitro cell culture conditions and reflect the behavior of isolated cells in artificial environments.

Signaling Pathway Analysis

Published mechanistic studies have used pathway-specific inhibitors, Western blot analysis, and phosphoproteomic approaches to map the intracellular signaling events downstream of AOD-9604 exposure in cultured adipocytes. Key findings from these in-vitro studies include:

• Activation of the beta-3 adrenergic receptor signaling cascade, as measured by cAMP accumulation assays
• Phosphorylation of hormone-sensitive lipase at serine residues associated with enzyme activation
• Engagement of the MAPK/ERK signaling pathway, documented by phospho-specific antibody detection
• Upregulation of uncoupling protein (UCP) gene expression in adipocyte cell lines, measured by RT-qPCR

These signaling observations provide mechanistic context for the lipolytic activity data and have been reproduced across independent research laboratories using different cell lines and assay methodologies.

IGF-1 Independence In Vitro

A distinguishing characteristic of AOD-9604 documented in published research is its independence from IGF-1 (Insulin-like Growth Factor 1) signaling pathways in in-vitro model systems. Full-length hGH activates the JAK2/STAT5 signaling axis in cell-based assays, which is the primary pathway leading to IGF-1 gene expression. Published studies have specifically examined whether AOD-9604 engages this signaling cascade.

Data from multiple in-vitro studies using liver cell lines, hepatocyte cultures, and GH receptor-expressing reporter cell systems consistently demonstrate that AOD-9604 does not activate JAK2/STAT5 signaling at concentrations where lipolytic activity is observed. Specifically:

• No JAK2 phosphorylation is detected by Western blot following AOD-9604 exposure in hepatocyte cell lines
• STAT5 reporter gene assays show no activation in response to AOD-9604, while responding robustly to full-length hGH positive controls
• IGF-1 mRNA levels, measured by RT-qPCR in liver cell cultures, are not affected by AOD-9604 at concentrations up to 100-fold above the effective concentration for lipolytic activity
• IGF-1 protein secretion into conditioned media, measured by ELISA, shows no change following AOD-9604 exposure

This IGF-1 independence is structurally consistent with the peptide's design, as the JAK2/STAT5 binding domains of hGH are located in the N-terminal and middle regions of the molecule (Site 1 and Site 2), which are entirely absent from the 176-191 C-terminal fragment. Published crystallographic data of the hGH-GH receptor complex confirms that the 176-191 region does not participate in the receptor dimerization interface required for JAK2/STAT5 activation.

Structural Characterization

The three-dimensional structure of AOD-9604 has been studied using NMR spectroscopy and circular dichroism (CD) in aqueous solution and membrane-mimetic environments. Published structural data reveal that the free peptide in aqueous solution adopts a predominantly disordered conformation, consistent with the behavior of short linear peptides lacking stabilizing tertiary structure elements.

In membrane-mimetic environments (such as SDS micelle or DPC micelle solutions), CD and NMR studies indicate that the peptide adopts a more ordered amphipathic conformation. This environment-dependent structural behavior is significant for researchers investigating the peptide's interaction with membrane-associated targets, as the lipid bilayer interface may serve as a structuring element that promotes the active conformation.

The disulfide bond between the two cysteine residues within the sequence contributes to structural stability. Published mass spectrometric and chromatographic analyses confirm that the intramolecular disulfide bond is critical for maintaining the peptide's activity profile in in-vitro assay systems, as reduced (linear) forms show substantially diminished activity in comparative studies.

Comparison with Native hGH Fragment 176-191

Researchers sometimes use both AOD-9604 (Tyr-hGH 177-191) and the unmodified native fragment (hGH 176-191) in comparative studies. Published data from side-by-side experiments in identical assay systems document several differences:

• AOD-9604 shows improved detection characteristics in HPLC and mass spectrometric analytical methods due to the N-terminal tyrosine's UV absorption and ionization properties
• The added tyrosine does not significantly alter receptor binding parameters in published competition binding assays
• AOD-9604 shows modestly improved stability in serum-containing media compared to the native fragment, based on published degradation kinetics studies
• Both forms show equivalent IGF-1 pathway independence in published comparative signaling studies

Adipogenesis Research In Vitro

Beyond lipolysis, published in-vitro research has examined AOD-9604 in the context of adipocyte differentiation (adipogenesis). Studies using 3T3-L1 pre-adipocyte cells -- a standard in-vitro model for adipogenesis research -- have investigated the peptide's effects on the differentiation program when added at various stages of the differentiation protocol.

Published data from Oil Red O staining, gene expression profiling (PPAR-gamma, C/EBP-alpha, aP2), and lipid accumulation quantification in these in-vitro systems provide additional context for understanding the peptide's activity profile in adipose cell biology research. These studies complement the lipolysis data by examining a different aspect of lipid metabolism regulation in controlled cell culture conditions.

Published Literature and Research History

AOD-9604 has been documented in the peer-reviewed scientific literature since the late 1990s, with the primary body of published work originating from Monash University and the affiliated Metabolic Pharmaceuticals research program. Subsequent publications from independent research groups have expanded the literature base and provided cross-validation of key findings.

The published record includes:

• Original characterization papers documenting the identification and activity profiling of the hGH 176-191 region
• Structure-activity relationship studies examining the impact of specific residue modifications on in-vitro activity
• Mechanistic signaling pathway analyses using pharmacological inhibitors and molecular biology techniques
• Comparative studies positioning AOD-9604 relative to full-length hGH and other hGH fragments in in-vitro assay systems
• Analytical chemistry publications describing validated methods for peptide quantification and purity assessment

Purity and Quality at Origin Research Labs

Origin Research Labs provides AOD-9604 at >99.760% purity, verified by independent third-party analysis from Janoshik Analytical. Each batch undergoes HPLC purity assessment, mass spectrometric identity confirmation (confirming correct molecular weight and disulfide bond formation), and residual solvent analysis. A Certificate of Analysis (COA) accompanies every order, supporting the integrity and reproducibility of downstream research applications.

Summary

AOD-9604 is a well-characterized modified fragment of human growth hormone amino acids 176-191 (CAS 221231-10-3). Published in-vitro research documents its activity in lipolytic signaling assays, its independence from IGF-1 pathways in cell-based models, and its selective engagement of specific intracellular signaling cascades. The compound's unique activity profile -- retaining lipolysis-related signaling while not activating JAK2/STAT5 or IGF-1 pathways in vitro -- makes it a valuable pharmacological tool for researchers investigating the modular activities of growth hormone and lipid metabolism signaling in controlled laboratory settings.